5. Bibliography
1. Goldberg A, Confino-Cohen R. Timing of venom skin tests and IgE
determinations after insect sting anaphylaxis. J Allergy Clin Immunol.
1997;100(2):182-184. doi:10.1016/s0091-6749(97)70222-7
2. Lafuente A, Javaloyes G, Berroa F, et al. Early skin testing is
effective for diagnosis of hypersensitivity reactions occurring during
anesthesia. Allergy. 2013;68(6):820-822. doi:10.1111/all.12154
3. Fisher MM. Intradermal testing after severe histamine reactions to
intravenous drugs used in anaesthesia. Anaesth Intensive Care.
1976;4(2):97-104. doi:10.1177/0310057X7600400202
4. Aalto-Korte K, Mäkinen-Kiljunen S. False negative SPT after
anaphylaxis. Allergy. 2001;56(5):461-462.
doi:10.1034/j.1398-9995.2001.056005461.x
5. Culp JA, Palis RI, Castells MC, Lucas SR, Borish L. Perioperative
anaphylaxis in a 44-year-old man. Allergy Asthma Proc.
2007;28(5):602-605. doi:10.2500/aap2007.28.3047
6. Soetens F, Rose M, Fisher M. Timing of skin testing after a suspected
anaphylactic reaction during anaesthesia. Acta Anaesthesiol Scand.
2012;56(8):1042-1046. doi:10.1111/j.1399-6576.2011.02643.x
7. Demoly P, Adkinson NF, Brockow K, et al. International Consensus on
drug allergy. Allergy. 2014;69(4):420-437. doi:10.1111/all.12350
8. Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of
anaphylaxis during anesthesia: 2011 updated guidelines for clinical
practice. J Investig Allergol Clin Immunol. 2011;21(6):442-453.
9. Li PH, Chiang V, Yeung HH, Au EY. Caution Against Temporary Tolerance
and Negative Skin Testing During the Anergic Period Following Systemic
Reactions. J Investig Allergol Clin Immunol. 2022;32(2):157-158.
doi:10.18176/jiaci.0724
10. Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: A 2022
practice parameter update. J Allergy Clin Immunol.
2022;150(6):1333-1393. doi:10.1016/j.jaci.2022.08.028
11. Mohamed OE, Baretto RL, Walker I, et al. Empty mast cell syndrome:
fallacy or fact? J Clin Pathol. 2020;73(5):250-256.
doi:10.1136/jclinpath-2019-206157
12. Xiang Z, Block M, Löfman C, Nilsson G. IgE-mediated mast cell
degranulation and recovery monitored by time-lapse photography. J
Allergy Clin Immunol. 2001;108(1):116-121. doi:10.1067/mai.2001.116124
13. Fukuishi N, Murakami S, Ohno A, et al. Does β-hexosaminidase
function only as a degranulation indicator in mast cells? The primary
role of β-hexosaminidase in mast cell granules. J Immunol.
2014;193(4):1886-1894. doi:10.4049/jimmunol.1302520
14. Balseiro-Gomez S, Flores JA, Acosta J, Ramirez-Ponce MP, Ales E.
Transient fusion ensures granule replenishment to enable repeated
release after IgE-mediated mast cell degranulation. J Cell Sci.
2016;129(21):3989-4000. doi:10.1242/jcs.194340
15. Hammel I, Lagunoff D, Krüger PG. Recovery of rat mast cells after
secretion: a morphometric study. Exp Cell Res. 1989;184(2):518-523.
doi:10.1016/0014-4827(89)90349-2
16. Seagrave J, Oliver JM. Antigen-dependent transition of IgE to a
detergent-insoluble form is associated with reduced IgE
receptor-dependent secretion from RBL-2H3 mast cells. J Cell Physiol.
1990;144(1):128-136. doi:10.1002/jcp.1041440117
17. Nagata Y, Suzuki R. FcεRI: A Master Regulator of Mast Cell
Functions. Cells. 2022;11(4):622. doi:10.3390/cells11040622
18. Adnan A, Acharya S, Alenazy LA, et al. Multistep IgE Mast Cell
Desensitization Is a Dose- and Time-Dependent Process Partially
Regulated by SHIP-1. J Immunol. 2023;210(6):709-720.
doi:10.4049/jimmunol.2100485
19. Huber M. Activation/Inhibition of mast cells by supra-optimal
antigen concentrations. Cell Commun Signal. 2013;11(1):7.
doi:10.1186/1478-811X-11-7
20. Gimborn K, Lessmann E, Kuppig S, Krystal G, Huber M. SHIP
down-regulates FcepsilonR1-induced degranulation at supraoptimal IgE or
antigen levels. J Immunol. 2005;174(1):507-516.
doi:10.4049/jimmunol.174.1.507
21. Hernandez-Hansen V, Smith AJ, Surviladze Z, et al. Dysregulated
FcepsilonRI signaling and altered Fyn and SHIP activities in
Lyn-deficient mast cells. J Immunol. 2004;173(1):100-112.
doi:10.4049/jimmunol.173.1.100
22. Leitges M, Gimborn K, Elis W, et al. Protein kinase C-delta is a
negative regulator of antigen-induced mast cell degranulation. Mol Cell
Biol. 2002;22(12):3970-3980. doi:10.1128/MCB.22.12.3970-3980.2002
23. Zhang J, Chiang YJ, Hodes RJ, Siraganian RP. Inactivation of c-Cbl
or Cbl-b differentially affects signaling from the high affinity IgE
receptor. J Immunol. 2004;173(3):1811-1818.
doi:10.4049/jimmunol.173.3.1811
24. Haddon DJ, Antignano F, Hughes MR, et al. SHIP1 is a repressor of
mast cell hyperplasia, cytokine production, and allergic inflammation in
vivo. J Immunol. 2009;183(1):228-236. doi:10.4049/jimmunol.0900427
25. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a
6-h 12-step protocol effective in 35 desensitizations in patients with
gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol
Oncol. 2004;95(2):370-376. doi:10.1016/j.ygyno.2004.08.002
26. Kato T, Kimata M, Tsuji T, et al. Role of protein kinase A in the
inhibition of human mast cell histamine release by β-adrenergic receptor
agonists. Allergology International. 2002;51(3):197-203.
doi:10.1046/j.1440-1592.2002.00265.x
27. Grönneberg R, Raud J. Effects of local treatment with salmeterol and
terbutaline on anti-IgE-induced wheal, flare, and late induration in
human skin. Allergy. 1996;51(10):685-692.
28. Cohan VL, Undem BJ, Fox CC, Adkinson NF, Lichtenstein LM, Schleimer
RP. Dexamethasone does not inhibit the release of mediators from human
mast cells residing in airway, intestine, or skin. Am Rev Respir Dis.
1989;140(4):951-954. doi:10.1164/ajrccm/140.4.951
29. Schleimer RP, Schulman ES, MacGlashan DW, et al. Effects of
dexamethasone on mediator release from human lung fragments and purified
human lung mast cells. J Clin Invest. 1983;71(6):1830-1835.
doi:10.1172/jci110938